| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8877245 | TEVA PHARMS INTL | Modified release dosage forms of skeletal muscle relaxants |
Nov, 2023
(5 months ago) | |
| US9399025 | TEVA PHARMS INTL | Modified release dosage forms of skeletal muscle relaxants |
Nov, 2023
(5 months ago) | |
| US7820203 | TEVA PHARMS INTL | Modified release dosage forms of skeletal muscle relaxants |
Nov, 2023
(5 months ago) | |
| US9375410 | TEVA PHARMS INTL | Modified release dosage forms of skeletal muscle relaxants |
Nov, 2023
(5 months ago) | |
| US7829121 | TEVA PHARMS INTL | Modified release dosage forms of skeletal muscle relaxants |
Nov, 2023
(5 months ago) | |
| US7544372 | TEVA PHARMS INTL | Modified release dosage forms of skeletal muscle relaxants |
Nov, 2023
(5 months ago) | |
| US7790199 | TEVA PHARMS INTL | Modified release dosage forms of skeletal muscle relaxants |
Nov, 2023
(5 months ago) | |
| US7387793 | TEVA PHARMS INTL | Modified release dosage forms of skeletal muscle relaxants |
Feb, 2025
(9 months from now) | |
Amrix is owned by Teva Pharms Intl.
Amrix contains Cyclobenzaprine Hydrochloride.
Amrix has a total of 8 drug patents out of which 7 drug patents have expired.
Expired drug patents of Amrix are:
- US8877245
- US9399025
- US7820203
- US9375410
- US7829121
- US7544372
- US7790199
Amrix was authorised for market use on 01 February, 2007.
Amrix is available in capsule, extended release;oral dosage forms.
Amrix can be used as relief of muscle spasm.
The generics of Amrix are possible to be released after 26 February, 2025.
Drugs and Companies using CYCLOBENZAPRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 01 February, 2007
Treatment: Relief of muscle spasm
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
AMRIX family patents
